Prevest Denpro Q2 FY27: consolidated PAT +15% YoY to ₹6.39 Cr as margins slip ~180bps
PAT +15.3% YoY · revenue +16.1% · margins compressing
₹21.64 Cr
+16.1% YoY
₹6.39 Cr
+15.3% YoY
27.56%
+0.5pp YoY
₹5.32
Prevest Denpro's consolidated Q2 FY27 (quarter ended September 30, 2026) revenue grew 16.1% year-on-year to ₹21.64 Cr (Q2 FY26: ₹18.64 Cr) and net profit rose 15.3% YoY to ₹6.39 Cr (₹5.54 Cr), with EPS at ₹5.32 versus ₹4.62. Sequentially the pace was similar — revenue +13.5% and PAT +13.3% over Q1 FY27's ₹19.07 Cr revenue and ₹5.64 Cr PAT — so the quarter extends rather than accelerates the recent run-rate. Profitability softened on both comparisons: net margin (PAT/total income) eased to 27.57% from 27.95% YoY and 27.66% QoQ, while operating margin fell to 34.05% from 35.83% YoY and 35.48% QoQ, as total expenses (₹14.79 Cr) grew faster than revenue. Neither period carries exceptional items, so reported and underlying growth are identical.
Q2 FY-2027 vs prior quarters
No street estimates for this micro-cap could be located, so the print cannot be checked against consensus. Management's last formal outlook, from the November 2025 concall, targeted revenue growth crossing 20% in H2 FY26 (a now-elapsed checkpoint) and a three-year ambition to cross ₹100 Cr in revenue via US scale-up; no fresh guidance accompanied this filing, so Q2 FY27 cannot be graded against a specific target. The half-year trend runs a touch ahead of the quarter: H1 FY27 consolidated revenue is up 18.3% YoY to ₹40.71 Cr and PAT up 20.9% to ₹12.03 Cr. Standalone PAT of ₹6.63 Cr (EPS ₹5.52) sits about 3.7% above the consolidated figure, reflecting a small drag from the two loss-making foreign subsidiaries, Axiodent Inc. and Prevest Denpro Gulf, whose combined half-year net loss of ₹0.47 Cr the auditors flagged as immaterial to the group. Alongside the results, the board approved a 10% interim dividend (₹1/share) for the half year, record date November 20, 2026. No management press release accompanied the filing.
The stock went into the print at ₹420, up 6.3% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters.
Management expects revenue growth to accelerate and cross 20% in H2 FY26, driven by a rebound in domestic sales and sustained export momentum. The company is committed to maintaining its high-margin profile by focusing on new value-added product lines, particularly in digital dentistry, disinfectants, and biomaterials.
W1
Whether operating margin (down ~178bps YoY to 34.05%) stabilizes or compresses further in Q3 FY27 as cost growth outpaces revenue
W2
Progress toward management's 3-year target to cross ₹100 Cr revenue via US (Axiodent) scale-up — H1 FY27 run-rate (~₹81 Cr annualized) still meaningfully short
W3
Whether H2 FY27 revenue growth sustains the H1 FY27 pace (+18.3% YoY), consistent with management's stated export/domestic rebound-led acceleration
Context's 'year-ago quarter' figures (rev ₹34.41cr, PAT ₹9.95cr, EPS 8.29) are actually H1 FY26 half-year data mislabeled as quarterly; true Q2 FY26 quarter comparable used from this filing's own column (rev ₹18.64cr, PAT ₹5.54cr, EPS 4.62). No exceptional items either period; standalone PAT runs ~3.7% above consolidated due to small foreign-subsidiary losses (~₹0.47cr H1 combined, immaterial per auditors).
Informational and educational content only. Not investment advice.